FR2936150A1 - Composition, to protect skin and mucous membranes against organophosphorus toxic product of type V or cyanogenic products, comprises polysaccharide dispersed in emollient, softener, preservative and perfume, in excipient or vehicle - Google Patents
Composition, to protect skin and mucous membranes against organophosphorus toxic product of type V or cyanogenic products, comprises polysaccharide dispersed in emollient, softener, preservative and perfume, in excipient or vehicle Download PDFInfo
- Publication number
- FR2936150A1 FR2936150A1 FR0805160A FR0805160A FR2936150A1 FR 2936150 A1 FR2936150 A1 FR 2936150A1 FR 0805160 A FR0805160 A FR 0805160A FR 0805160 A FR0805160 A FR 0805160A FR 2936150 A1 FR2936150 A1 FR 2936150A1
- Authority
- FR
- France
- Prior art keywords
- compositions according
- dermatological compositions
- polysaccharide
- skin
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 14
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 14
- 239000002304 perfume Substances 0.000 title claims abstract description 5
- 239000003755 preservative agent Substances 0.000 title claims abstract description 5
- 239000003974 emollient agent Substances 0.000 title claims abstract description 4
- 231100000331 toxic Toxicity 0.000 title claims description 13
- 230000002588 toxic effect Effects 0.000 title claims description 13
- 210000004400 mucous membrane Anatomy 0.000 title claims 3
- 230000000515 cyanogenic effect Effects 0.000 title claims 2
- 150000004676 glycans Chemical class 0.000 title abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 title abstract 2
- 230000002335 preservative effect Effects 0.000 title abstract 2
- -1 softener Substances 0.000 title description 7
- 230000000699 topical effect Effects 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 15
- 229920001577 copolymer Polymers 0.000 claims description 12
- 150000004804 polysaccharides Chemical class 0.000 claims description 12
- 239000003440 toxic substance Substances 0.000 claims description 12
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- VAMFXQBUQXONLZ-UHFFFAOYSA-N icos-1-ene Chemical compound CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 6
- ZSZRUEAFVQITHH-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)ethyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CC(=C)C(=O)OCCOP([O-])(=O)OCC[N+](C)(C)C ZSZRUEAFVQITHH-UHFFFAOYSA-N 0.000 claims description 4
- 229920001586 anionic polysaccharide Polymers 0.000 claims description 4
- 150000004836 anionic polysaccharides Chemical class 0.000 claims description 4
- 125000006001 difluoroethyl group Chemical group 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- 229920001519 homopolymer Polymers 0.000 claims description 4
- WMZHDICSCDKPFS-UHFFFAOYSA-N triacontene Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCC=C WMZHDICSCDKPFS-UHFFFAOYSA-N 0.000 claims description 4
- 239000004373 Pullulan Substances 0.000 claims description 3
- 229920001218 Pullulan Polymers 0.000 claims description 3
- 235000019423 pullulan Nutrition 0.000 claims description 3
- 231100000167 toxic agent Toxicity 0.000 claims description 3
- 239000004902 Softening Agent Substances 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- LOPVAWVHGAWUPS-UHFFFAOYSA-M [2-hydroxy-3-(2-methylprop-2-enoyloxy)propyl]-trimethylazanium;chloride Chemical compound [Cl-].CC(=C)C(=O)OCC(O)C[N+](C)(C)C LOPVAWVHGAWUPS-UHFFFAOYSA-M 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 6
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000004205 dimethyl polysiloxane Substances 0.000 description 15
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 15
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 15
- 229940008099 dimethicone Drugs 0.000 description 13
- 239000000126 substance Substances 0.000 description 10
- 231100000481 chemical toxicant Toxicity 0.000 description 9
- 230000001681 protective effect Effects 0.000 description 9
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
- 230000004888 barrier function Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 5
- 230000007480 spreading Effects 0.000 description 5
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 4
- MXOAEAUPQDYUQM-UHFFFAOYSA-N chlorphenesin Chemical compound OCC(O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 150000002903 organophosphorus compounds Chemical class 0.000 description 4
- WYMSBXTXOHUIGT-UHFFFAOYSA-N paraoxon Chemical compound CCOP(=O)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 WYMSBXTXOHUIGT-UHFFFAOYSA-N 0.000 description 4
- 229960004623 paraoxon Drugs 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 4
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 4
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 3
- FBNAWLJSQORPAX-UHFFFAOYSA-N 4-methyl-3-propan-2-ylphenol Chemical compound CC(C)C1=CC(O)=CC=C1C FBNAWLJSQORPAX-UHFFFAOYSA-N 0.000 description 3
- SPAGIJMPHSUYSE-UHFFFAOYSA-N Magnesium peroxide Chemical compound [Mg+2].[O-][O-] SPAGIJMPHSUYSE-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- LHJQIRIGXXHNLA-UHFFFAOYSA-N calcium peroxide Chemical compound [Ca+2].[O-][O-] LHJQIRIGXXHNLA-UHFFFAOYSA-N 0.000 description 3
- 229940078916 carbamide peroxide Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 229920006037 cross link polymer Polymers 0.000 description 3
- VTIIJXUACCWYHX-UHFFFAOYSA-L disodium;carboxylatooxy carbonate Chemical compound [Na+].[Na+].[O-]C(=O)OOC([O-])=O VTIIJXUACCWYHX-UHFFFAOYSA-L 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000000622 irritating effect Effects 0.000 description 3
- USSBDBZGEDUBHE-UHFFFAOYSA-L magnesium;2-oxidooxycarbonylbenzoate Chemical compound [Mg+2].[O-]OC(=O)C1=CC=CC=C1C([O-])=O USSBDBZGEDUBHE-UHFFFAOYSA-L 0.000 description 3
- 231100000435 percutaneous penetration Toxicity 0.000 description 3
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229960001922 sodium perborate Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- 239000004343 Calcium peroxide Substances 0.000 description 2
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940073736 biosaccharide gum-4 Drugs 0.000 description 2
- 235000019402 calcium peroxide Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 239000002917 insecticide Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229960004995 magnesium peroxide Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 229920001522 polyglycol ester Polymers 0.000 description 2
- 235000010333 potassium nitrate Nutrition 0.000 description 2
- 239000004323 potassium nitrate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 229940045872 sodium percarbonate Drugs 0.000 description 2
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- UZVUJVFQFNHRSY-OUTKXMMCSA-J tetrasodium;(2s)-2-[bis(carboxylatomethyl)amino]pentanedioate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CC[C@@H](C([O-])=O)N(CC([O-])=O)CC([O-])=O UZVUJVFQFNHRSY-OUTKXMMCSA-J 0.000 description 2
- UUJLHYCIMQOUKC-UHFFFAOYSA-N trimethyl-[oxo(trimethylsilylperoxy)silyl]peroxysilane Chemical compound C[Si](C)(C)OO[Si](=O)OO[Si](C)(C)C UUJLHYCIMQOUKC-UHFFFAOYSA-N 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- XXMBEHIWODXDTR-UHFFFAOYSA-N 1,2-diaminoethanol Chemical compound NCC(N)O XXMBEHIWODXDTR-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical class CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- 241000223651 Aureobasidium Species 0.000 description 1
- 241000223678 Aureobasidium pullulans Species 0.000 description 1
- 229920001342 Bakelite® Polymers 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 240000009226 Corylus americana Species 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 241000272060 Elapidae Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 229920000289 Polyquaternium Polymers 0.000 description 1
- CVBNMWXECPZOLM-UHFFFAOYSA-N Rhamnetin Natural products COc1cc(O)c2C(=O)C(=C(Oc2c1)c3ccc(O)c(O)c3O)O CVBNMWXECPZOLM-UHFFFAOYSA-N 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- DYAHQFWOVKZOOW-UHFFFAOYSA-N Sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- JJIUCEJQJXNMHV-UHFFFAOYSA-N VX nerve agent Chemical compound CCOP(C)(=O)SCCN(C(C)C)C(C)C JJIUCEJQJXNMHV-UHFFFAOYSA-N 0.000 description 1
- 241001639412 Verres Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- PJVJTCIRVMBVIA-JTQLQIEISA-N [dimethylamino(ethoxy)phosphoryl]formonitrile Chemical compound CCO[P@@](=O)(C#N)N(C)C PJVJTCIRVMBVIA-JTQLQIEISA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229940089837 amygdalin Drugs 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 239000004637 bakelite Substances 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 101150062523 bath-39 gene Proteins 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940085262 cetyl dimethicone Drugs 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- LFHISGNCFUNFFM-UHFFFAOYSA-N chloropicrin Chemical compound [O-][N+](=O)C(Cl)(Cl)Cl LFHISGNCFUNFFM-UHFFFAOYSA-N 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- DLINORNFHVEIFE-UHFFFAOYSA-N hydrogen peroxide;zinc Chemical compound [Zn].OO DLINORNFHVEIFE-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- GIKLTQKNOXNBNY-OWOJBTEDSA-N lewisite Chemical compound Cl\C=C\[As](Cl)Cl GIKLTQKNOXNBNY-OWOJBTEDSA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 125000005481 linolenic acid group Chemical group 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- OUHCLAKJJGMPSW-UHFFFAOYSA-L magnesium;hydrogen carbonate;hydroxide Chemical compound O.[Mg+2].[O-]C([O-])=O OUHCLAKJJGMPSW-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940031722 methyl gluceth-20 Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229940048869 o-cymen-5-ol Drugs 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 239000010702 perfluoropolyether Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 229960001841 potassium permanganate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- CZPZWMPYEINMCF-UHFFFAOYSA-N propaneperoxoic acid Chemical compound CCC(=O)OO CZPZWMPYEINMCF-UHFFFAOYSA-N 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940024463 silicone emollient and protective product Drugs 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000003009 skin protective agent Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- HOAUAOBUGFYWMK-UHFFFAOYSA-M sodium;propanoate;hydrate Chemical compound O.[Na+].CCC([O-])=O HOAUAOBUGFYWMK-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940061605 tetrasodium glutamate diacetate Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229940105296 zinc peroxide Drugs 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Abstract
Description
La présente invention se rapporte au domaine des nécessités de la vie et plus particulièrement au domaine de la dermatologie et de la cosmétique. Lors de conflits ou d'actes terroristes, des composés chimiques hautement toxiques peuvent, être utilisés. Ces agents, capables de traverser la barrière cutanée, peuvent provoquer des dégâts tissulaires irréversibles et être fatals pour les personnes exposées. Ces agents toxiques de guerre incluent des produits chimiques organophosphorés comme les agents G (sarin, tabun, roman, GF) et les agents V (VX) ainsi que des produits chimiques vésicants tels que l'ypérite au soufre (sulfure de dichloroéthyle) (HD) et la lewisite. Les zones de peau naturellement exposées, lorsqu'elles ne sont pas recouvertes par une tenue, un appareil respiratoire à air filtré, des gants ou d'autres dispositifs de protection, peuvent néanmoins être protégées par l'utilisation de protecteurs topiques cutanés afin d'éviter les effets particulièrement délétères des agents chimiques toxiques. A cette fin on utilise selon l'invention des compositions topiques à effet barrière. La présente invention vise plus particulièrement la protection des personnels militaires ou civils, exposés à des agents chimiques toxiques pouvant pénétrer au travers de la barrière cutanée et induire des dégâts irrémédiables dans l'organisme. Plus précisément, l'invention concerne des compositions protectrices cutanées contre des agents chimiques toxiques. En effet, l'exposition de la peau à des agents chimiques toxiques est fréquente. Il est souvent souhaitable, voire nécessaire, de prévenir le contact cutané de ces agents chimiques aussi efficacement que possible. Par exemple, beaucoup d'insecticides, notamment organophosphorés, présentent des risques potentiels pour les personnes qui les répandent, soit par contact soit par inhalation. On connaissait déjà des compositions dermatologiques à base d'homopolymère de vinylpyrrolidone (PVP) et de copolymère de 2-méthacryloyloxyéthylphosphorylcholine (poly MPC) qui ont été divulguées dans le brevet français FR 2 846 555. Ces compositions sont utilisées en tant que barrière épidermique, pour limiter ou supprimer les effets cutanés irritants ou allergisants de différentes substances, notamment les effets allergisants du nickel et les effets irritants de molécules tensioactives comme le laurylsulfate de sodium. Cependant, de telles compositions n'ont pas été jusqu'ici utilisées comme 5 protection contre les composés organophosphorés ou contre ceux de la famille des ypérites. Dans la demande de brevet antérieur n° 08/01999 déposée le 11 avril 2008 les sociétés demanderesses ont décrit et revendiqué une association d'un 10 homopolymère de N-vinyl 2-pyrrolidone ou d'un copolymère de vinylpyrrolidone/triacontène ou de vinylpyrrolidone/eicosène avec un copolymère de 2ùméthacryloyloxyéthyl phosphorylcholine/méthacrylate d'alkyle ou un copolymère de 2ùméthacryloyloxyéthyl phosphoryl choline/chlorure de 2-hydroxy 3-méthacryloyl oxypropyl triméthylammonium, dans une composition topique 15 dermoprotectrice. Une telle association manifeste un net effet synergique. Des copolymères de vinylpyrrolidone et d'a-oléfines, notamment, de triacontène et d'eicosène ont été utilisés dans des compositions dermatologiques et cosmétiques comme décrit, notamment, dans les brevets français FR 2 751 212 et FR 2 782 918. Toutefois, aucun effet protecteur contre des agents toxiques 20 chimiques ne leur est attribué. La demande de brevet antérieure avait donc pour objet des compositions dermatologiques et/ou cosmétiques protectrices contre les agents chimiques toxiques tels que les agents organophosphorés et ceux de la famille des ypérites, associant ces deux types d'agents dermo protecteurs. 25 Or les sociétés demanderesses viennent de trouver et c'est ce qui constitue l'objet de la présente demande de brevet, qu'il est possible de se protéger contre les dangers liés à l'exposition aux produits chimiques organophosphorés et notamment au toxique Paraoxon et aux agents V comme le toxique dénommé 30 ainsi que vis-à-vis des produits irritants tels que la chloropicrine, ou toxiques tels que les produits cyanogénétiques tels que les cyanures métalliques, les nitriles organiques comme le nitrile mandelique, les cyanohydrines ou les glucosides cyanés comme l'Amygdaline.... The present invention relates to the field of the necessities of life and more particularly to the field of dermatology and cosmetics. During conflicts or terrorist acts, highly toxic chemical compounds may be used. These agents, capable of crossing the skin barrier, can cause irreversible tissue damage and be fatal to exposed individuals. These toxic warfare agents include organophosphorus chemicals such as G agents (sarin, tabun, novel, GF) and V agents (VX) as well as vesicant chemicals such as sulfur yperite (dichloroethyl sulfide) (HD). ) and lewisite. Areas of naturally exposed skin, when not covered by clothing, filtered air respirators, gloves or other protective devices, may nevertheless be protected by the use of topical cutaneous avoid the particularly deleterious effects of toxic chemicals. For this purpose, topical compositions having a barrier effect are used according to the invention. The present invention aims more particularly the protection of military personnel or civilians, exposed to toxic chemical agents that can penetrate through the skin barrier and induce irreparable damage in the body. More specifically, the invention relates to cutaneous protective compositions against toxic chemical agents. Indeed, exposure of the skin to toxic chemicals is common. It is often desirable, if not necessary, to prevent skin contact with these chemicals as effectively as possible. For example, many insecticides, especially organophosphorus insecticides, pose potential risks to those who spread them, either by contact or by inhalation. Dermatological compositions based on homopolymer of vinylpyrrolidone (PVP) and of 2-methacryloyloxyethylphosphorylcholine copolymer (poly MPC) which have been disclosed in French Patent FR 2,846,555 have already been known. These compositions are used as epidermal barrier, to limit or eliminate the irritating or allergenic skin effects of various substances, in particular the allergenic effects of nickel and the irritating effects of surfactant molecules such as sodium lauryl sulphate. However, such compositions have not hitherto been used as protection against organophosphorus compounds or those of the yperite family. In the earlier patent application No. 08/01999 filed on April 11, 2008 the applicant companies have described and claimed a combination of a homopolymer of N-vinyl 2-pyrrolidone or a copolymer of vinylpyrrolidone / triacontene or vinylpyrrolidone / eicosene with a copolymer of 2-methacryloyloxyethyl phosphorylcholine / alkyl methacrylate or a copolymer of 2-methacryloyloxyethyl phosphoryl choline / 2-hydroxy-3-methacryloyl oxypropyl trimethylammonium chloride, in a dermoprotective topical composition. Such an association has a clear synergistic effect. Copolymers of vinylpyrrolidone and α-olefins, especially triacontene and eicosene have been used in dermatological and cosmetic compositions as described, in particular, in French patents FR 2 751 212 and FR 2 782 918. However, no protective effect against toxic chemicals is assigned to them. The prior patent application therefore relates to dermatological and / or cosmetic compositions that protect against toxic chemical agents such as organophosphorus agents and those of the yperite family, combining these two types of dermo-protective agents. The plaintiff companies have just found, and this is the subject of the present patent application, that it is possible to protect oneself against the dangers related to exposure to organophosphorus chemicals, and in particular to the toxic Paraoxon. and agents V as the so-called toxic as well as irritating substances such as chloropicrin, or toxic such as cyanogenetic products such as metal cyanides, organic nitriles such as mandelic nitrile, cyanohydrins or glucosides cyanids like Amygdalin ....
35 Or les sociétés demanderesses viennent de trouver d'une manière surprenante que dans le cas d'une attaque par un toxique du type V (comme le toxique VN) une excellente protection pouvait être assurée par des gels à base de polysaccharides. Ce résultat peut paraître surprenant dans la mesure ou les résultats antérieurs avec les dérivés organophosphorés indiquaient que de meilleurs résultats étaient obtenus avec des gels anhydres plutôt qu'avec des émulsions à phase continue aqueuse (huile/eau) 10 En particulier les gels aqueux contenant des polysaccharides assurent une protection immédiate et d'une durée importante garantissant une sécurité satisfaisante pendant au moins 30 minutes ce qui en cas d'attaque ou de contact avec des produits toxiques du type V permet d'assurer les premiers secours et 15 d'organiser la décontamination. However, the applicants have surprisingly found that in the case of an attack by a type V toxic (such as the VN toxic) excellent protection could be provided by polysaccharide-based gels. This result may seem surprising in that previous results with organophosphorus derivatives indicated that better results were obtained with anhydrous gels than with aqueous continuous phase (oil / water) emulsions. polysaccharides provide immediate and long-term protection ensuring satisfactory safety for at least 30 minutes, which in case of attack or contact with toxic products type V provides first aid and 15 organize the decontamination.
Les polysaccharides utilisés dans les compositions selon l'invention sont des composés produits par fermentation bactérienne de plantes ou de farines végétales tels que le pullulan , le fucogel , le rham nosoft , le glycopatch , et 20 le glycofilm c'est-à-dire des poly homosaccharides solubles dans l'eau ou dispersibles dans l'eau. The polysaccharides used in the compositions according to the invention are compounds produced by bacterial fermentation of plants or vegetable flours such as pullulan, fucogel, rham nosoft, glycopatch, and glycofilm, that is to say poly homosaccharides soluble in water or dispersible in water.
Par ailleurs l'efficacité de tels gels pourra être renforcé par l'addition de produits barrière tels que ceux décrits dans la demande de brevet antérieure comme par 25 exemple les homopolymères de N-vinyl 2- pyrrolidone ou les copolymères de vinyl pyrrolidone/triacontène ou de vinylpyrrolidone/eicosene avec un copolymère de 2-méthacryloyloxyéthyl phosphorylcholine/chlorure de 2- hydroxy 3-methacryloyoxypropyl triméthylammonium. Ces composés sont ajoutés isolément ou en mélange. 30 Selon un mode de réalisation particulier des compositions selon l'invention les compositions dermatologiques contiennent en outre un ou plusieurs agents détoxifiants, non toxiques et acceptables dermatologiquement. Ces agents détoxifiants sont introduits dans les compositions en pourcentage massique 35 variant de 0,001 à 50%.5 Ces agents détoxifiants connus sont choisis parmi les agents oxydants comme le peroxyde de benzoyle, le peroxyde de zinc, le monoperoxyphtalate de magnésium, le perborate de sodium, le percarbonate de sodium, le permanganate de potassium, le peroxyde carbamide (peroxyde d'urée), le peroxyde de calcium, le dioxyde de titane, l'acide perpropionique, le peroxyde de magnésium ; les agents soufrés comme la N-acétyl cystéine, ou des agents neutralisants comme l'oxyde de zinc, les agents complexants comme l'acide étidronique et son sel tétrasodique, l'acide 1-hydroxyéthylènediamine (1,1-diphosphonique), le propionate de sodium, l'hydroxy carbonate de magnésium, le nitrate de potassium, l'acide thioglycolique. En outre, les compositions dermatologiques et/ou cosmétiques selon l'invention peuvent contenir un ou plusieurs polymères complémentaires choisis parmi le polyperfluoroethoxy méthoxydifluoro éthyl PEG phosphate, le copolymère de diméthicone et de vinyldiméthicone, le copolymère de diéthylèneglycol, d'acide adipique et de glycérine, le Polysilicone-8 et les polyglycérides d'acides oléique/linoléique/ linolénique dont le rôle est de rendre plus agréable et surtout plus aisée l'application des compositions selon l'invention sur les parties du corps exposées aux effets de l'agent toxique. Moreover, the effectiveness of such gels can be enhanced by the addition of barrier products such as those described in the earlier patent application, such as, for example, homopolymers of N-vinyl-2-pyrrolidone or copolymers of vinylpyrrolidone / triacontene or of vinylpyrrolidone / eicosene with a copolymer of 2-methacryloyloxyethyl phosphorylcholine / 2-hydroxy-3-methacryloyoxypropyl trimethylammonium chloride. These compounds are added alone or as a mixture. According to one particular embodiment of the compositions according to the invention, the dermatological compositions also contain one or more detoxifying agents, which are non-toxic and dermatologically acceptable. These detoxifying agents are introduced into the compositions in weight percent ranging from 0.001 to 50%. These known detoxifying agents are chosen from oxidizing agents such as benzoyl peroxide, zinc peroxide, magnesium monoperoxyphthalate and sodium perborate. , sodium percarbonate, potassium permanganate, carbamide peroxide (peroxide of urea), calcium peroxide, titanium dioxide, perpropionic acid, magnesium peroxide; sulfur-containing agents such as N-acetyl cysteine, or neutralizing agents such as zinc oxide, complexing agents such as etidronic acid and its tetrasodium salt, 1-hydroxyethylenediamine (1,1-diphosphonic acid), propionate sodium hydroxide, magnesium hydroxy carbonate, potassium nitrate, thioglycolic acid. In addition, the dermatological and / or cosmetic compositions according to the invention may contain one or more complementary polymers chosen from polyperfluoroethoxy methoxydifluoroethyl PEG phosphate, the copolymer of dimethicone and vinyldimethicone, the copolymer of diethyleneglycol, adipic acid and glycerine. Polysilicone-8 and polyglycerides of oleic / linoleic / linolenic acids whose role is to make it more pleasant and above all easier to apply the compositions according to the invention to the parts of the body exposed to the effects of the toxic agent. .
Le Glycopatch utilisé pour la présente invention est un polysaccharide anionique de haut poids moléculaire (2x10" Da) commercialisé par la firme la Biochimie Appliquée SOLABIA. Il se présente sous la forme d'une solution visqueuse à 2% dans l'eau. Il est utilisé à une concentration s'échelonnant de 0,1 à 10% en poids. Il est obtenu par un procédé biotechnique de fermentation utilisant comme substrat, du sorbitol végétal de maïs et de l'extrait autolytique de levures (Saccharomyces cerevisae). Le Glycopatch est un polymère ramifié désacétylé dont l'unité répétitive est composée de L. Fucose, de D-Glucose et d'acide glucuronique. Le Glycopatch possède la capacité de former des matrices tridimensionnelles dont 30 la résistance et la texture peuvent être modulées en fonction des ingrédients qu'on lui associe. Il manifeste un effet seconde peau objectivé sur la protection contre les substances chimiques agressives comme le Sodium (Dodecyl Sulfate). Sa 35 dénomination INCI est Biosaccharide gum-4 Le PULLULAN (HAYASHIBARA) est un polysaccharide naturel obtenu par fermentation de l'amidon d'origine 100% végétale par Aureobasidium pullulans. L'actif se présente sous forme d'une poudre soluble dans l'eau. Il a des propriétés d'adhésion et ses propriétés anti-oxydantes ont été démontrées dans la prévention de l'oxydation des actifs cosmétiques et des parfums vis-à-vis de l'oxygène Identité chimique : Natural Polysaccharide Le FOMBLIN HC/P2-1000 (SOLVAY) est un grade de perfluoropolyethers, très peu soluble dans l'eau, insoluble dans l'huile, soluble dans les solvants polaires (éthanol) Il a des propriétés de répellance à l'huile et à l'eau, non irritant, protecteur cutané contre les agressions par des irritants solubles dans l'huile et des irritants solubles dans l'eau. INCI: polyperfluoroethoxymethoxy difluoroethyl PEG phosphate. Sa teneur varie de 1 à 20% en poids. Il forme ainsi une couche intermédiaire dans les émulsions eau dans l'huile ou huile dans l'eau et renforce ainsi l'effet barrière de la préparation. The glycopatch used for the present invention is a high molecular weight anionic polysaccharide (2x10 "Da) marketed by SOLABIA Applied Biochemistry, which is in the form of a 2% viscous solution in water. used at a concentration ranging from 0.1 to 10% by weight It is obtained by a biotechnical fermentation process using as a substrate, vegetable sorbitol of corn and autolytic extract of yeasts (Saccharomyces cerevisae). is a deacetylated branched polymer whose repeating unit is composed of L. Fucose, D-Glucose and glucuronic acid The Glycopatch has the ability to form three-dimensional matrices whose resistance and texture can be modulated according to ingredients it is associated with.It has a second skin effect objectified on the protection against aggressive chemicals such as Sodium (Dodecyl Sulfate). INCI name is Biosaccharide gum-4 PULLULAN (HAYASHIBARA) is a natural polysaccharide obtained by fermentation of starch of 100% vegetable origin by Aureobasidium pullulans. The active ingredient is in the form of a powder soluble in water. It has adhesion properties and its antioxidant properties have been demonstrated in the prevention of oxidation of cosmetic active ingredients and perfumes vis-à-vis oxygen Chemical identity: Natural Polysaccharide The FOMBLIN HC / P2-1000 (SOLVAY) is a grade of perfluoropolyethers, very slightly soluble in water, insoluble in oil, soluble in polar solvents (ethanol) It has properties of repellance to oil and water, non-irritating, skin protector against aggression by oil-soluble irritants and water-soluble irritants. INCI: polyperfluoroethoxymethoxy difluoroethyl PEG phosphate. Its content varies from 1 to 20% by weight. It thus forms an intermediate layer in water-in-oil or oil-in-water emulsions and thus reinforces the barrier effect of the preparation.
Le polymère de diméthicone et de vinyldiméthicone est notamment celui commercialisé sous la marque Silicone Elastomer Blend DC9041. Le copolymère de diéthylèneglycol, d'acide adipique et de glycérine est notamment celui commercialisé sous la marque Lexorez 100. The dimethicone and vinyldimethicone polymer is especially that marketed under the trademark Silicone Elastomer Blend DC9041. The copolymer of diethylene glycol, adipic acid and glycerin is in particular that sold under the trademark Lexorez 100.
Le polysilicone-8 est notamment celui commercialisé sous la marque Silicone Plus Polymère VS80Dry. Ces polymères complémentaires sont introduits en pourcentage massique variant par exemple de 0,005% à 10%. Polysilicone-8 is in particular that marketed under the brand Silicone Plus Polymer VS80Dry. These complementary polymers are introduced in mass percentage varying for example from 0.005% to 10%.
Les compositions dermatologiques selon l'invention peuvent renfermer, en outre, des agents émollients, des agents adoucissants, des agents conservateurs ou des agents parfumants Les compositions dermatologiques peuvent se présenter sous forme de gel, de lotion, d'émulsion huile dans l'eau, de dispersion, de lait, de crème, d'onguent, de mousse, de bâton, de spray, d'aérosols ou sous toute autre forme appropriée à l'application topique. A cette fin, les principes actifs sont dissous ou dispersés dans un excipient ou un véhicule inerte non toxique, cosmétiquement acceptable comme des matières grasses, de l'eau, de l'alcool, du propylène glycol, contenant en outre des agents conservateurs, des agents dispersants, de la lanoline ou de la vaseline. On utilise la composition dermatologique et/ou cosmétique en tant qu'agent protecteur cutané vis-à-vis des agents chimiques toxiques tels que ceux de la famille des composés organophosphorés et plus particulièrement ceux de la série V et le Paraoxon. Les compositions selon l'invention sont destinées à être appliquées sur la peau, notamment en prévention et en prévision d'un éventuel contact avec des agents chimiques toxiques. Elles sont appliquées en couche suffisante pour exercer un effet barrière. Les compositions dermatologiques selon l'invention contiennent donc une base protectrice du type polysaccharide et un ou plusieurs agents détoxifiants, afin, d'une part de retarder la pénétration cutanée des agents chimiques toxiques organophosphorés du type V et d'autre part de les neutraliser avant qu'ils puissent atteindre leurs sites d'action dans l'organisme vivant. L'efficacité protectrice des compositions dermatologiques a été évaluée selon les protocoles I et II. The dermatological compositions according to the invention may further contain emollients, softening agents, preserving agents or perfuming agents. The dermatological compositions may be in the form of a gel, a lotion or an oil-in-water emulsion. , dispersion, milk, cream, ointment, mousse, stick, spray, aerosol or any other form suitable for topical application. For this purpose, the active ingredients are dissolved or dispersed in a non-toxic, cosmetically acceptable inert carrier or vehicle such as fats, water, alcohol, propylene glycol, further containing preservatives, dispersants, lanolin or petroleum jelly. The dermatological and / or cosmetic composition is used as a cutaneous protective agent with respect to toxic chemical agents such as those of the family of organophosphorus compounds and more particularly those of the V series and Paraoxon. The compositions according to the invention are intended to be applied to the skin, especially in prevention and in anticipation of a possible contact with toxic chemical agents. They are applied in a layer sufficient to exert a barrier effect. The dermatological compositions according to the invention therefore contain a protective base of the polysaccharide type and one or more detoxifying agents, in order, on the one hand, to retard the skin penetration of the toxic organophosphorus type V chemical agents and, on the other hand, to neutralize them beforehand. that they can reach their sites of action in the living organism. The protective efficacy of dermatological compositions was evaluated according to Protocols I and II.
L'efficacité détoxifiante des agents détoxifiants a été évaluée selon le protocole III. Les exemples suivants illustrent l'invention, sans toutefois la limiter. 35 5 Exemple I Gel barrière aqueux : A 16 Ingrédients % % le mieux indiqué à l'essai Biosaccharide Gum-4 0,1-10 0,6 Natural 0,1-10 2 Polysaccharide (Aureobasidium pullulons) Ethanol 23 Gomme xanthane 0,1-5 1 Polyperfluoroethoxymethoxy 1-20 5 Difluoroethyl PEG Phosphate (Fomblin HC/P2-1000) Eau purifiée Qsp 100 Exemple II Crème barrière H/E : E 32 Ingrédients % % le mieux indiqué à l'essai Glyceryl stéarate & PEG-100 2 stéarate Polydecene hydrogéné 15 Triacontanyl - PVP 1-5 4 Dimethicone/Vinyl 0,1-5 5 Dimethicone cross polymer & silice (DC 9701) Dimethicone& 1-25 15 trimethylsiloxisilicate (DC593) Polyperfluoroethoxymethoxy 1-20 5 Difluoroethyl-PEG Phosphate (Fomblin HC/P2-1000) PVP/Polycarbamyl/polyglycolester/ 0,1-10 5 Phenoxyethanol & Parabens Hydroxypropylcellulose & 1-10 5 Methylgluceth-20& water& Phenoxyethanol& parabens Potassium Cetyl Phosphate 1-4 1 Polyquaternium-51 0,001-0,5 0,05 (1% d'une solution à 5%) Butylene glycol 1 Chlorphenesine 0,3 o-Cymen-5ol 0,1 Eau purifiée Qsp 100 7 105 Exemple III Crème barrière E/H : F 54 Ingrédients % % le mieux indiqué à l'essai Cetyl dimethicone copolyol 1-5 3,5 Dimethicone 0,1-2 0,5 Stearyl Dimethicone 1-5 3 Polydecene hydrogené 16 Lanoline 3 Glycérine 2 Dimethicone& 1-10 5 trimethylsiloxysilicate (DC593) Dimethicone/Vinyl 0,1-10 ! 5 Dimethicone crosspolymère & silice (DC 9701) ' Polyperfluoroethoxymethoxy 1-20 5 ll;~l., -l.. 1 DUC! Phosphate (Fomblin HC/P2-1000) PVP Chlorure d'aluminium Butylene glycol Chlorphenesine o-Cymen-5ol Polyquaternium-51 Eau purifiée Exemple IV E 28 CONSTITUANTS % qté fabriquée Nomenclature INCI SIMULSOL 165 2 8 Glyceryl Stearate & PEG-100 Stearate NEXBASE 2006 21 84 Hydrogenated Polydecene ANTARON WP 660 4 16 Tricontanyl PVP DC 9701 5 20 dimethicone/vinyl dimethicone crosspolymer & silica DC 593 5 20 Dimethicone et triméthylsiloxysilicate EAU PURIFIEE 0,1 0,4 Aqua (Water) NATRASOL 250 HHR 0,5 2 HydroxyEthylCellulose FOMBLIN HC/P2-1000 10% 50 200 Polyperfluoroethoxymethoxydifluoroethyl PEG phosphate AQUAMERE H1212 5 20 PVP/Polycarbamyl/polyglycol ester / phenonip AMPHISOL K 1 4 Potassium Cetyl Phosphate LIPIDURE PMB 4 16 Polyquaternium - 51 BUTYLENE GLYCOL-1,3 2 8 Butylene Glycol CHLORPHENESINE BP 0,3 1,2 Chlorphenesin BIOSOL 0,1 0,4 o-Cymen-5-ol Total 100 400 8 0,1-10 1-10 1 0,3 0,1 0,001-0,5 0,05(1% d'une solution à 5%) Qsp 100 L'efficacité des compositions protectrices a été évaluée selon les protocoles suivants Protocole I pénétration transmembranaire du VX sur membrane synthétique Protocole II pénétration percutanée du VX sur peau d'oreille de porcs dermatomée pénétration percutanée du VX sur peau humaine dermatomée PROTOCOLE I Test d'évaluation des compositions protectrices (TSP), préparation et montage des membranes synthétiques sur cellules de diffusion statiques Ces études ont été effectuées sur des échantillons dermatomés de peau de porc et 20 de peau humaine disposés dans des cellules de diffusion statiques. Objectifs En utilisant des modèles in vitro de peau (membrane de silicone (polydiméthylsiloxane), on a determiné l'efficacité d'une formulation protectrice 25 de la peau, vis-à-vis d'un composé organophosphoré. The detoxifying effectiveness of detoxifying agents was evaluated according to protocol III. The following examples illustrate the invention without limiting it. EXAMPLE I Aqueous Barrier Gel: A 16 Ingredients%% Best Tested Biosaccharide Gum-4 0.1-10 0.6 Natural 0.1-10 2 Polysaccharide (Aureobasidium pullulons) Ethanol 23 Xanthan Gum 0, 1-5 1 Polyperfluoroethoxymethoxy 1-20 Difluoroethyl PEG Phosphate (Fomblin HC / P2-1000) Purified water Qsp 100 Example II H / E barrier cream: E 32 Ingredients%% best suited for testing Glyceryl stearate & PEG-100 Hydrogenated Polydecene Stearate Triacontanyl - PVP 1-5 4 Dimethicone / Vinyl 0.1-5 Dimethicone cross polymer & silica (DC 9701) Dimethicone & 1-25 trimethylsiloxisilicate (DC593) Polyperfluoroethoxymethoxy 1-20 Difluoroethyl-PEG Phosphate (Fomblin HC / P2-1000) PVP / Polycarbamyl / polyglycolester / 0.1-10 Phenoxyethanol & Parabens Hydroxypropylcellulose 1- Methylgluceth-20 & water & Phenoxyethanol & parabens Potassium Cetyl Phosphate 1-4 1 Polyquaternium-51 0.001-0.5 0, 05 (1% of a 5% solution) Butylene glycol 1 Chlorphenesine 0.3 o-Cymen-5ol 0.1 Water purified Qsp 100 7 105 Example III W / O barrier cream: F 54 Ingredients%% best suited for testing Cetyl dimethicone copolyol 1-5 3,5 Dimethicone 0.1-2 0.5 Stearyl Dimethicone 1-5 3 Polydecene hydrogenated 16 Lanolin 3 Glycerin 2 Dimethicone & 1-10 5 trimethylsiloxysilicate (DC593) Dimethicone / Vinyl 0.1-10! Dimethicone Crosspolymer & Silica (DC 9701) Polyperfluoroethoxymethoxy 1-20 5 ll; -1 .1. 1 DUC! Phosphate (Fomblin HC / P2-1000) PVP Aluminum Chloride Butylene Glycol Chlorphenesine o-Cymen-5ol Polyquaternium-51 Purified Water Example IV E 28 CONSTITUENTS% qty manufactured INCI Nomenclature SIMULSOL 165 2 8 Glyceryl Stearate & PEG-100 Stearate NEXBASE 2006 Hydrogenated Polydecene ANTARON WP 660 4 16 Tricontanyl PVP DC 9701 5 dimethicone / vinyl dimethicone crosspolymer & silica DC 593 5 Dimethicone and trimethylsiloxysilicate WATER PURIFIED 0.1 0.4 Aqua (Water) NATRASOL 250 HHR 0.5 2 HydroxyEthylcellulose FOMBLIN HC / P2-1000 10% 50 200 Polyperfluoroethoxymethoxydifluoroethyl PEG phosphate AQUAMERE H1212 5 PVP / Polycarbamyl / polyglycol ester / phenonip AMPHISOL K 1 4 Potassium Cetyl Phosphate LIPIDURE PMB 4 16 Polyquaternium - 51 BUTYLENE GLYCOL-1,3 2 8 Butylene Glycol CHLORPHENESINE BP 0.3 1,2 Chlorphenesin BIOSOL 0.1 0.4 o-Cymen-5-ol Total 100 400 8 0.1-10 1-10 1 0.3 0.1 0.001-0.5 0.05 (1 % of a 5% solution) Qsp 100 The effectiveness of the protective compositions was evaluated according to the following protocols Protocol I VX transmembrane penetration on synthetic membrane Protocol II percutaneous penetration of VX on porcine ear skin dermatomed percutaneous penetration of VX on dermatomed human skin PROTOCOL I Evaluation test of protective compositions (TSP), preparation and Mounting Synthetic Membranes on Static Diffusion Cells These studies were performed on dermatomic samples of porcine skin and human skin disposed in static diffusion cells. Objectives Using in vitro skin models (silicone membrane (polydimethylsiloxane), the effectiveness of a skin-protecting formulation against an organophosphorus compound was determined.
L'efficacité a été déterminée par rapport à un produit protecteur de référence testé dans les mêmes conditions expérimentales. 30 Matériels et réactifs 1. Matériels - Membrane synthétique Membrane de silicone : (PDMS, 0,4 mm d'épaisseur, Samco silicone products, UK). 35 - Cellules de diffusion en pyrex fabriquées à façon par un verrier Laboratoires VERRE LABO-MULA, 18 av. de l'industrie BP 391, 69960 COBRAS France. Efficacy was determined relative to a reference protective product tested under the same experimental conditions. Materials and Reagents 1. Materials - Synthetic Membrane Silicone Membrane: (PDMS, 0.4 mm thick, Samco silicone products, UK). 35 - Pyrex diffusion cells custom made by a glassmaker Laboratoires VERRE LABO-MULA, 18 av. of industry BP 391, 69960 COBRAS France.
La surface de la membrane exposée est de 1.13 cm2, le compartiment donneur peut-être ouvert ou fermé (bouchon bakélite + joint Téflon) ce qui permet ainsi de travailler dans des conditions occlusives ou non occlusives. Le volume du compartiment receveur est d'environ 4m1. The surface of the exposed membrane is 1.13 cm2, the donor compartment may be open or closed (bakelite stopper + Teflon seal) which allows to work in occlusive or non-occlusive conditions. The volume of the receiving compartment is about 4m1.
- Des barreaux magnétiques de 5 à 7 mm de longueur sont utilisés pour homogénéiser le milieu de survie dans le compartiment receveur de la cellule de diffusion. 2. Réactifs • Le milieu de survie de base est celui utilisé avec les explants cutanés Hank's Buffer Saline Solution (HBSS), Gibco (Invitrogen), rèf 14175-046100 ml. 15 Un tampon phosphate sera envisagé, le Phosphate Buffer Solution (PBS). Les membranes synthétiques n'étant pas un matériel biologique, la prolifération bactérienne est inexistante et par conséquent, un tampon phosphate serait suffisant. o Composé organophosphoré à évaluer 20 o Composition protectrice à évaluer (TSP) Magnetic rods 5 to 7 mm in length are used to homogenize the survival medium in the receiving compartment of the diffusion cell. 2. Reagents • The basic survival medium is that used with the Hank's Buffer Saline Solution (HBSS), Gibco (Invitrogen) skin explants, ref. 14175-046100 ml. A phosphate buffer will be considered, the Phosphate Buffer Solution (PBS). Synthetic membranes are not biological material, bacterial proliferation is non-existent and therefore a phosphate buffer would be sufficient. o Organophosphorus compound to be evaluated 20 o Protective composition to be evaluated (TSP)
Conditions expérimentales Experimental conditions
o Cellules de diffusion de type cellules de Frantz statiques 25 o Conditions non occlusives o Milieu de survie de la membrane o Température, bain-marie 39°C (maintien de la température de la membrane à 31-32°C) o Humidité (mesurée) 30 o Durée du test : 6 heures o Quantité de toxique déposée : dépôt de 4,9 l de PDX à l'aide d'une micropipette, dépôt de la goutte au milieu de la cellule sans l'étaler à la surface de la membrane. o Surface de la membrane exposée : 1,13 cm2 Dispositifs de protection cutanée testés o Static Frantz Cell Diffusion Cells 25 Non-Occlusive Conditions o Membrane Survival Environment o Temperature, water bath 39 ° C (maintain membrane temperature at 31-32 ° C) o Moisture (measured) O Duration of the test: 6 hours o Quantity of deposited toxin: deposit of 4.9 l of PDX using a micropipette, deposit of the drop in the middle of the cell without spreading it on the surface of the membrane. o Exposed membrane surface: 1.13 cm2 Skin protection devices tested
o Quantité déposée : 5 mg/cm2, (48 mg pour une membrane de 9,62 cm2) 5 o Etalement à la surface de la membrane o Dépôt sur la membrane 15 min avant le dépôt de toxique. o Amount deposited: 5 mg / cm 2, (48 mg for a 9.62 cm 2 membrane). o Spreading on the membrane surface o Deposition on the membrane 15 min before the deposition of toxic.
Protocole d'étalement de la TSP sur la membrane Protocol for spreading TSP on the membrane
- tarer la membrane - dépôt d'une noisette de TSP sur un bord de la membrane. - A l'aide d'une marise (spatule en silicone souple), étaler la TSP en allant de gauche à droite, puis de bas en haut, avec plusieurs passages si nécessaire toujours dans le même sens. - tare the membrane - deposit a small amount of TSP on one edge of the membrane. - Using a tide (spatula soft silicone), spread the TSP from left to right, then from bottom to top, with several passages if necessary always in the same direction.
20 --- Sens de l'étalement M Membrane -- TSP 25 - peser la membrane : Si m> 48 mg -+ repasser la marise une fois de gauche à droite de façon à enlever de la TSP Si m< 48 mg--> repasser la marise une fois avec les résidus de TSP dessus de façon à les réétaler. 30 - renouveler l'opération jusqu'à atteindre une masse de TSP proche de 48 mg. 20 - Sense of spreading M Membrane - TSP 25 - weigh membrane: If m> 48 mg - + iron bedding once from left to right to remove TSP If m <48 mg-- > iron the tail once with TSP residues on top to re-spread. 30 - repeat the operation until reaching a mass of TSP close to 48 mg.
Lots Test effectué sur 12 cellules de diffusion. 35 N=6 cellules par topique. 11 10 15 PROTOCOLE II Etude de la pénétration percutanée de l'agent toxique VX sur un modèle de peau d'oreilles de porc dermatomée ou sur peau humaine dermatomée Lots Test performed on 12 diffusion cells. N = 6 cells per topic. 11 10 15 PROTOCOL II Study of the percutaneous penetration of the toxic agent VX on a model of dermatomée pig ear skin or on dermatomée human skin
Cette détermination est effectuée par rapport à un témoin sans composé barrière en utilisant la préparation de l'exemple IV (E 28), la préparation de l'exemple I (A 16), la préparation de l'exemple II (E32) et le mélange 70/30 des composés de l'exemple 4 et de l'exemple 5, en fonction du temps. This determination is made with respect to a control without a barrier compound using the preparation of Example IV (E 28), the preparation of Example I (A 16), the preparation of Example II (E32) and the preparation of 70/30 mixture of the compounds of Example 4 and Example 5, as a function of time.
Les valeurs sont exprimées en % QO (QO étant la quantité de toxique déposée à la 15 surface de la membrane). The values are expressed in% QO (QO being the amount of toxic deposited on the surface of the membrane).
On peut constater que la pénétration de l'agent VX est maximale pour la préparation témoin. Les compositions selon l'invention diminuent très sensiblement la pénétration et la préparation de l'exemple IV assure une 20 protection encore plus importante. It can be seen that the penetration of the VX agent is maximal for the control preparation. The compositions according to the invention substantially reduce the penetration and the preparation of Example IV provides even greater protection.
Protocole d'étalement de la TSP sur la peau dermatomée 25 Application de la TSP Protocol for spreading TSP on dermatomeal skin 25 Application of TSP
Après avoir monté les peaux sur les cellules de diffusion et une fois stabilisée (mesure de la perte insensible en eau et de la température) After mounting the skins on the scattering cells and once stabilized (measuring the insensitive loss in water and temperature)
30 tarer un morceau de parafilm avec une noisette de TSP en son centre Enrouler le parafilm autour du doigt avec la TSP à l'extérieur et sur le bout du doigt Appliquer avec des mouvements circulaires la TSP sur la peau en commençant par le centre de l'échantillon cutané. Peser le parafilm pour connaître la quantité de TSP déposée. Les résultats obtenus sont rassemblés dans la figure 1. 45 35 40 PROTOCOLE III Etude de l'activité détoxifiante vis-à-vis du Paraoxon de 15 substances chimiques 1- les substances actives testées Elles ont été numérotées de 1 à 15, Hydroxyde carbonate de magnésium (1) 10 Peroxyde de calcium (2) Peroxyde de magnésium (3) Dioxyde de titane micronisé, géométrie anatase (Eusolex T) (4) Dioxyde de titane micronisé, géométrie rutile (MT100TV) (5) Oxyde de zinc micronisé (Z-cote) (6) 15 Tétrasodium glutamate diacétate (7) Acide 1-hydroxyéthylène 1,1 û disphosphonique (8) Perborate de sodium (9) Nitrate de potassium (10) Peroxyde de carbamide (11) 20 Acide thioglycolique (12) Monoperoxyphtalate de magnésium (13) Percarbonate de sodium (14) Propionate de sodium (15) 30 tare a piece of parafilm with a hazelnut of TSP in the center Wrap the parafilm around the finger with the TSP outside and on the tip of the finger Apply with circular movements the TSP on the skin starting from the center of the cutaneous sample. Weigh the parafilm to know the amount of TSP deposited. The results obtained are collated in FIG. 1. 45 35 40 PROTOCOL III Study of the detoxification activity with respect to the Paraoxon of 15 chemical substances 1- the active substances tested They were numbered from 1 to 15, hydroxide carbonate of magnesium (1) 10 Calcium peroxide (2) Magnesium peroxide (3) Micronized titanium dioxide, anatase geometry (Eusolex T) (4) Micronized titanium dioxide, rutile geometry (MT100TV) (5) Micronized zinc oxide (Z -cote) (6) Tetrasodium glutamate diacetate (7) 1-hydroxyethylene 1,1-disphosphonic acid (8) Sodium perborate (9) Potassium nitrate (10) Carbamide peroxide (11) 20 Thioglycolic acid (12) Monoperoxyphthalate Magnesium (13) Sodium Percarbonate (14) Sodium Propionate (15)
25 2- Le toxique testé Il s'agit d'une substance organophosphorée, le paraoxon appelé PDX 3- Le protocole d'étude 30 La substance active et le PDX sont incorporés dans une solution tampon ; les études ont été effectuées à deux pH différents : à pH=7,4 ou à pH=11 2- The Toxic Test It is an organophosphorus substance, the paraoxon called PDX 3- The study protocol The active substance and the PDX are incorporated in a buffer solution; the studies were carried out at two different pHs: pH = 7.4 or pH = 11
Deux ratios ont été étudiés : un mélange un pour un entre la substance active et 35 le PDX ou un mélange dix pour un. Two ratios were studied: a one-to-one mixture between the active substance and PDX or a ten-to-one mixture.
La dégradation du PDX est mesurée par spectrophotométrie UV à 400 nanomètres pendant 1 heure. Une mesure est faite toutes les 5 minutes. The degradation of PDX is measured by UV spectrophotometry at 400 nanometers for 1 hour. A measurement is made every 5 minutes.
40 4- Les résultats et conclusion L'ensemble des résultats est regroupé selon les conditions de pH et les ratios utilisés. Les substances les plus actives pour dégrader le PDX dans ces conditions sont • L'acide 1- hydroxyéthylène 1,1-diphosphonique 45 • Le perborate de sodium • Le peroxyde de carbamide 505 40 4- The results and conclusion The results are grouped according to the pH conditions and the ratios used. The most active substances for degrading PDX under these conditions are • 1-hydroxyethylene 1,1-diphosphonic acid 45 • Sodium perborate • Carbamide peroxide 505
Claims (14)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0805160A FR2936150B1 (en) | 2008-09-19 | 2008-09-19 | NEW DERMATOLOGICAL COMPOSITIONS PROTECTING THE SKIN AND MUCOUS MEMBRANES |
| FR0901669A FR2929847B1 (en) | 2008-04-11 | 2009-04-06 | DERMATOLOGICAL AND / OR COSMETIC COMPOSITION PROTECTING THE SKIN AND MUCOUS MEMBRANES |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0805160A FR2936150B1 (en) | 2008-09-19 | 2008-09-19 | NEW DERMATOLOGICAL COMPOSITIONS PROTECTING THE SKIN AND MUCOUS MEMBRANES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2936150A1 true FR2936150A1 (en) | 2010-03-26 |
| FR2936150B1 FR2936150B1 (en) | 2013-09-06 |
Family
ID=42028009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR0805160A Active FR2936150B1 (en) | 2008-04-11 | 2008-09-19 | NEW DERMATOLOGICAL COMPOSITIONS PROTECTING THE SKIN AND MUCOUS MEMBRANES |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2936150B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2349298A1 (en) * | 2008-11-10 | 2011-08-03 | Aboca S.p.A. Societa' Agricola | Method for the preparation of medical devices and devices obtained therefrom |
| US20220008324A1 (en) * | 2016-08-08 | 2022-01-13 | Ahava - Dead Sea Laboratories Ltd. | Compositions comprising dead sea water and polysaccharides and uses thereof as skin protectants |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001070271A2 (en) * | 2000-03-23 | 2001-09-27 | Collaborative Technologies, Inc. | Acid-stable base compositions for preparing surfactant free topical compositions |
| US20020051797A1 (en) * | 2000-01-04 | 2002-05-02 | Bruce Jezior | Dermal barrier composition |
| US6403653B1 (en) * | 2000-06-02 | 2002-06-11 | The United States Of America As Represented By The Secretary Of The Army | Active topical skin protectants using reactive nanoparticles |
| US6699485B1 (en) * | 1999-08-04 | 2004-03-02 | Ausimont S.P.A. | Cosmetic compositions |
| FR2846555A1 (en) * | 2002-10-31 | 2004-05-07 | Biorga Lab | Dermatological or cosmetic composition, useful e.g. for treating dry skin and protecting against allergens, contains a vinylpyrrolidone homopolymer and a copolymer based on phosphorylcholine |
| DE10301851A1 (en) * | 2003-01-17 | 2004-07-29 | Lts Lohmann Therapie-Systeme Ag | Use of dialkylaminoalkylphenyl carbamate derivatives to protect humans from poisoning by cholinesterase inhibitors, including pesticides and chemical warfare agents |
| WO2011012394A1 (en) * | 2009-07-31 | 2011-02-03 | Evonik Stockhausen Gmbh | Skin protectant, particularly against hydrophobic (lipohilic) and against hydrophilic (lipophobic) harmful substances |
-
2008
- 2008-09-19 FR FR0805160A patent/FR2936150B1/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6699485B1 (en) * | 1999-08-04 | 2004-03-02 | Ausimont S.P.A. | Cosmetic compositions |
| US20020051797A1 (en) * | 2000-01-04 | 2002-05-02 | Bruce Jezior | Dermal barrier composition |
| WO2001070271A2 (en) * | 2000-03-23 | 2001-09-27 | Collaborative Technologies, Inc. | Acid-stable base compositions for preparing surfactant free topical compositions |
| US6403653B1 (en) * | 2000-06-02 | 2002-06-11 | The United States Of America As Represented By The Secretary Of The Army | Active topical skin protectants using reactive nanoparticles |
| FR2846555A1 (en) * | 2002-10-31 | 2004-05-07 | Biorga Lab | Dermatological or cosmetic composition, useful e.g. for treating dry skin and protecting against allergens, contains a vinylpyrrolidone homopolymer and a copolymer based on phosphorylcholine |
| DE10301851A1 (en) * | 2003-01-17 | 2004-07-29 | Lts Lohmann Therapie-Systeme Ag | Use of dialkylaminoalkylphenyl carbamate derivatives to protect humans from poisoning by cholinesterase inhibitors, including pesticides and chemical warfare agents |
| WO2011012394A1 (en) * | 2009-07-31 | 2011-02-03 | Evonik Stockhausen Gmbh | Skin protectant, particularly against hydrophobic (lipohilic) and against hydrophilic (lipophobic) harmful substances |
Non-Patent Citations (3)
| Title |
|---|
| DOW CORNING: "SkinShield", 31 March 2005 (2005-03-31), XP002642531, Retrieved from the Internet <URL:http://www.dowcorning.com/content/publishedlit/00706.pdf?DCWS=Beauty%20and%20Personal%20Care&DCWSS=> [retrieved on 20110616] * |
| GREVEN HAUTSCHUTZ: "Ligana Mult-tec", INTERNET CITATION, 10 June 2008 (2008-06-10), pages 1 - 2, XP002593714, Retrieved from the Internet <URL:http://www.peter-greven-hautschutz.de/fileadmin/user_upload/produkte/ D_LIGANA_MULTI_TEC_LOTION_WA_V2.pdf> [retrieved on 20100727] * |
| STOCKHAUSEN: "Travabon und Travabon S", INTERNET CITATION, 2005, pages 1 - 6, XP002593712, Retrieved from the Internet <URL:http://www.leber-gmbh.de/Downloads/Datenblaetter/Hautschutz/Travabon.pdf> [retrieved on 20100727] * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2349298A1 (en) * | 2008-11-10 | 2011-08-03 | Aboca S.p.A. Societa' Agricola | Method for the preparation of medical devices and devices obtained therefrom |
| US20220008324A1 (en) * | 2016-08-08 | 2022-01-13 | Ahava - Dead Sea Laboratories Ltd. | Compositions comprising dead sea water and polysaccharides and uses thereof as skin protectants |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2936150B1 (en) | 2013-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2940051A1 (en) | MULTI-COMPONENT ANTI-TRANSPIRANT AGENT COMPRISING TWO COMPONENTS CAPABLE OF COOPERATING AND METHOD FOR TREATING HUMAN TRANSPIRATION IN TWO STEPS | |
| Hellgren et al. | On the effect of urea on human epidermis | |
| EP0673643B1 (en) | Cosmetic composition containing an association of superoxide dismutase and porphyrine | |
| WO2007122343A1 (en) | Cosmetic rinsable mask type composition for skin care | |
| FR3081711A1 (en) | METHOD FOR TOPICAL PROTECTION AGAINST ATMOSPHERIC POLLUTANT MOLECULES AND / OR FREE RADICALS FORMED BY EXPOSURE TO ULTRAVIOLET RADIATION | |
| EP0830126B1 (en) | Stabilized pseudo-emulsions and their preparation process | |
| FR2729050A1 (en) | Synergistic compsn. with microbicidal properties | |
| FR2809004A1 (en) | Use of topically applied ellagic acid, its salts, metal complexes and mono- or poly-ether or mono- or poly-acyl derivatives or its carbonates or carbamates with hydroxyl groups as an anti-pollution cosmetic | |
| CA2379824A1 (en) | Novel use of hypo-osmotic saline solutions and medicine based on said solutions | |
| EP1230914A1 (en) | Topical anti-pollution composition | |
| FR2945447A1 (en) | ECTOPARASITICIDE COMPOSITION AND METHOD FOR CONTROLLING ECTOPARASITES | |
| WO2008081095A2 (en) | Use of gamma-aminobutyric acid as a depigmentation agent | |
| FR2936150A1 (en) | Composition, to protect skin and mucous membranes against organophosphorus toxic product of type V or cyanogenic products, comprises polysaccharide dispersed in emollient, softener, preservative and perfume, in excipient or vehicle | |
| FR2846555A1 (en) | Dermatological or cosmetic composition, useful e.g. for treating dry skin and protecting against allergens, contains a vinylpyrrolidone homopolymer and a copolymer based on phosphorylcholine | |
| FR2929847A1 (en) | Composition, useful e.g. to protect skin against toxic chemical agents of organophosphate compounds, comprises e.g. N-vinyl 2-pyrrolidone homopolymer, and 2-methacryloyloxyethyl phosphorylcholine/alkyl methacrylate- copolymer | |
| FR2940064A1 (en) | ANTI-TRANSPARENT AGENT COMPRISING COMPONENTS CAPABLE OF FORMING COVALENT BONDS BETWEEN THEM AND METHOD OF TREATING HUMAN TWO STEP TRANSPIRATION | |
| CA2157749C (en) | Plant compound used for the binding of a perfume in a cosmetic and/or dermatologic composition | |
| EP3022214A1 (en) | Polymerised cerium oxide nanoparticles in an active or bioactive network, protective topical treatments, methods for preparation thereof and uses thereof | |
| RU2713948C2 (en) | Oral care composition | |
| EP1166746B1 (en) | Water-in-oil emulsion composition with a variable shear rate | |
| FR2929846A1 (en) | Cosmetic composition, useful e.g. to protect skin against toxic chemical agent, comprises combination of e.g. homopolymer of N-vinyl 2-pyrrolidone and copolymer of 2-methacryloyloxyethyl phosphorylcholine | |
| JP3333428B2 (en) | External preparation for skin | |
| FR2837388A1 (en) | Use of a deacetylated branched anionic polysaccharide as a film-forming agent for protecting keratinized surfaces against pollutants, especially heavy metals | |
| EP3849671B1 (en) | Use of reotier water to limit skin penetration of pollutants | |
| FR3138613A1 (en) | Topical anti-aging cosmetic composition comprising flocculosin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Decision of inpi director general to approve request for restoration | ||
| PLFP | Fee payment |
Year of fee payment: 9 |
|
| PLFP | Fee payment |
Year of fee payment: 10 |
|
| PLFP | Fee payment |
Year of fee payment: 11 |
|
| PLFP | Fee payment |
Year of fee payment: 12 |
|
| PLFP | Fee payment |
Year of fee payment: 13 |
|
| PLFP | Fee payment |
Year of fee payment: 14 |
|
| PLFP | Fee payment |
Year of fee payment: 15 |
|
| PLFP | Fee payment |
Year of fee payment: 16 |